The axonal microtubule-associated protein TAU, involved in Alzheimer's disease (AD), can be found in the extracellular space where it could be taken up by neurons, an event that is believed to contribute to the propagation of tau pathology in the brain. Since the small GTPase Rab7A is involved in the trafficking of endosomes, autophagosomes, and lysosomes, and RAB7A gene expression and protein levels are upregulated in AD patients, we tested the hypothesis that Rab7A was involved in tau secretion. We previously reported that both primary cortical neurons and HeLa cells over-expressing human TAU can release tau. Using these two cellular systems, we demonstrated that Rab7A regulates tau secretion. Upon Rab7A deletion, tau secretion was decreased.
In Alzheimer's disease (AD), TAU becomes hyperphosphorylated and self-aggregates into insoluble filaments called paired helical filaments that form neurofibrillary tangles in the somato-dendritic compartment (Lee et al. 2001; Cairns et al. 2007; Iqbal et al. 2016) . The degree of dementia correlates with the number of neurofibrillary tangles (Tomlinson et al. 1970; Alafuzoff et al. 1987; Braak and Braak 1991; Arriagada et al. 1992; Bierer et al. 1995) . TAU pathology is also observed in fronto-temporal lobar degeneration representing 5-15% of all dementia and including fronto-temporal dementia with Parkinsonism linked to chromosome 17 (Hutton et al. 1998; Poorkaj et al. 1998; Cairns et al. 2007; Kumar-Singh and Van Broeckhoven 2007) . At least 40 mutations in the TAU gene have been identified which are responsible for 10-20% of fronto-temporal dementia with Parkinsonism linked to chromosome 17 familial cases (Poorkaj et al. 2001; Rademakers et al. 2004; Kumar-Singh and Van Broeckhoven 2007) . No mutation in TAU gene is linked to AD.
TAU was also shown to accumulate in the extracellular space in AD. The presence of extracellular TAU was revealed by its accumulation in the CSF during the progression of the disease, which was believed to correlate with neuronal cell death (Hampel et al. 2010) . More recently, the presence of tau in the interstitial fluid in the absence of neurodegeneration was demonstrated by microdialysis in tau transgenic mouse brain showing that tau was released by neurons in vivo (Yamada et al. 2011) . Neuronal activity was shown to increase tau release by neurons both in vitro and in vivo (Pooler et al. 2013; Yamada et al. 2014) . Furthermore, we reported that the induction of autophagy and/or lysosomal dysfunction increased the release of tau by primary cortical neurons (Mohamed et al. 2014) .
The secretion of tau seems to occur through unconventional secretory pathways, which could involve structures such as late endosomes, autophagosomes, and lysosomes (Mohamed et al. 2013) . However, the contribution of these structures to tau secretion remains to be demonstrated. The small GTPase, Rab7A is involved in the trafficking of endosomes, autophagosomes, and lysosomes. It regulates membrane trafficking from early to late endosomes (Press et al. 1998; Girard et al. 2014) , from late endosomes to lysosomes (Feng et al. 1995; Ceresa and Bahr 2006) and from autophagosomes to lysosomes (Jager et al. 2004) . Rab7A is also implicated in lysosome biogenesis by regulating the fusion between late endosomes and lysosomes, and the homotypic fusion of lysosomes (Bucci et al. 2000) . In a recent study, Rab7A was also shown to be involved in unconventional secretion (Jae et al. 2015) . Interestingly, in basal forebrain, frontal cortex and hippocampus of mild cognitive impairment and AD patients, RAB7A gene expression, and protein levels were reported to be up-regulated (Ginsberg et al. 2010a (Ginsberg et al. ,b, 2011 . More recently, an increase in RAB7A gene expression was noted in pretangle-bearing nucleus basalis neurons (Tiernan et al. 2016) . Lastly, it was shown that the protein levels of RAB7A were increased in the CSF of AD patients (Armstrong et al. 2014) . In present study, our hypothesis was that Rab7A was involved in tau secretion. Our results showed that either suppression or inactivation of Rab7A resulted in a decrease in tau secretion, whereas an activation of Rab7A increased tau secretion. Our results indicate that the increase in RAB7A noted in AD could enhance secretion of TAU.
Materials and methods
Chemicals, antibodies, and plasmids MG-132 (Sigma, Oakville, ON, Canada) was used at a final concentration of 10 lM in HeLa cells. For immunoblotting, the following antibodies were used: total tau (1 : 15000 #A0024, Dako, Santa Clara, CA, USA, AB_10013724); Rab7A (1 : 1000 #R4779; Sigma, AB_477460); Flag (1 : 11000 #F3165; Sigma, AB_259529); c-actin (1 : 10000 #Sc-65635; Santa Cruz, Dallas, TX, USA, AB_1120816); LC3I/II (1 : 3000 #ab51520; Abcam, Cambridge, MA, USA, AB_881429); tau46 (1 : 1000 #ab22261; Abcam, AB_446931); green fluorescent protein (GFP) (1 : 1000 #3H9; Chromotek Inc., Hauppauge, NY, USA, AB_10773374); tau-1 (1 : 5000 #MAB3420; Millipore, Etobicoke, ON, Canada, AB_94855); tau-5 (1 : 1000 #QF215086; Thermo Scientific, Waltham, MA, USA, AB_2536235); Myc (1 : 1000 #sc-40; Santa Cruz, AB_627268); pS404 (1 : 1000 #OPA1-03143; Thermo Scientific, AB_2139851); pS202 (1 : 1000 #44-768G; Thermo Scientific, AB_2533749); pS422 (1 : 1000 #44-764G; Thermo Scientific, AB_2533748), and pT181 (1 : 1000 #MN1050; Thermo Scientific, AB_223651). For immunofluorescence microscopy, the following antibodies were used: tau-1 (1 : 200, #MAB3420; Millipore, AB_10013724) and A0024 (1 : 1000, #A0024; Dako, AB_10013724). The plasmids FLAG-4R-TAU and pEGFP-C1 used for transfection of HeLa cells were described previously (Plouffe et al. 2012) . pRc/CMV vector was used as empty vector for cotransfections (Invitrogen, Carlsbad, CA, USA). The plasmids GFP-RAB7-T22N, Flag-RAB7-Q86L, GFP-RAB7-Q86L, pCMV BiPMyc were purchased from Addgene (Cambridge, MA, USA). Flag-RAB7-Q86L and GFP-RAB7-Q86L were a gift from Qing Zhong (Addgene plasmids #28050 and #28049) (Sun et al. 2010) . GFP-RAB7-T22N was gift from Richard Pagano (Addgene plasmid #12660) (Choudhury et al. 2002) . pCMV BiP-Myc was a gift from Ron Prywes (Addgene plasmid # 27164) (Shen et al. 2002) .
siRNA oligos and libraries A human ON-TARGETplus Smartpool siRNA was used to knockdown RAB7A in HeLa cells (L-010388-00-0005; Thermo Scientific). The siRNA oligos were as follows:
A non-targeting siRNA pool (D-001810-10-20; Thermo Scientific) was used as control. In rat cortical neurons, an Accell Rat Smartpool siRNA was used to knockdown Rab7A (E-089334-00-0005; Thermo Scientific). The siRNA oligos were as follows: Rab7A siRNA: 5 0 -GCGUGAUGCCAAUAAAAUU-3 0 ; Rab7A
0 . An Accell non-targeting siRNA pool (D-001910-10-05; Thermo Scientific) was used as control.
Cell culture
HeLa cells were purchased from ATCC (Manassas, VA, USA, CVCL_0030) and were maintained at 37°C and 5% CO 2 in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and 2 mM glutamine (Wisent Life Sciences, Saint-Bruno, QC, Canada). Rat cortical neurons were dissected from E18 rat embryos (Charles River, Montr eal, QC, Canada) and cultured as previously described (Mohamed et al. 2014) . The use of animals and all surgical procedures described in this article were carried out according to The guide to the Care and Use of Experimental Animals of the Canadian Council on Animal Care. The ethical approval was obtained from the Animal care and ethics committee of the Centre de recherche du Centre Hospitalier de l'Universit e de Montr eal (CRCHUM) (protocol numbers N14002NLs and N14001NLrs).
siRNA and plasmid transfection For siRNA transfection, HeLa cells were plated into wells/plates and transfected the next day with siRNA (final concentration of 100 nM) using Dharmafect1 (Dharmacon, Lafayette, CO, USA). Twenty-four hours after siRNA transfection, cells were transfected either with Flag-4R-TAU, pEGFP or BIP-Myc plasmid using Genejuice (Novagene, Darmstadt, Germany) and 48 h post-transfection, cells were either lysed for immunoblotting or processed for electron microscopy. Neurons were treated with Accell siRNAs in Neurobasal medium (final concentration of 1 lM) 4 days after their plating. Neuronal cultures were harvested 4 days after adding the siRNAs in ice-cold Radioimmunoprecipitation assay buffer (TrisHCl pH 7.5 50 mM, NaCl 150 mM, Triton X-100 0.5%, sodium deoxycholate 0.5%, sodium dodecyl sulfate 0.1%, NaF 50 mM, Na3VO4 5 mM, and protease inhibitor cocktail (MilliporeSigma, Darmstadt, Germany). GFP or Flag-RAB7 plasmids were transfected in HeLa cells using Genejuice 24 h after plating. The following day, cells were transfected with Flag-4R-TAU plasmid using Genejuice. At 48 h post-transfection with TAU plasmid, cells were either lysed for immunoblotting or fixed on coverslips for immunofluorescence.
For the experiments where increasing amounts of TAU plasmids were used, a total of 1 lg of plasmids was transfected in HeLa cells using Genejuice 24 h after plating. The plasmids solution contained a combination of an increasing quantity of FLAG-TAU plasmids and a decreasing quantity of empty pCMV6 plasmids. At 48 h posttransfection, cells were lysed for immunoblotting.
Western blotting
The culture medium of HeLa cells containing TAU was collected 48 h after transfection and centrifuged at 1000 g for 10 min at 23°C to remove cell debris. The medium was directly mixed with Laemmli sample buffer and processed for immunoblotting. For cell lysates, cells were washed twice with phosphate-buffered saline and then lysed in fresh lysis buffer containing 0.1% Triton X-100 and protease inhibitor cocktail 19 (Complete EDTA-free from Roche Diagnostics, Indianapolis, IN, USA) and then incubated on ice for 10 min. Equal amount of the culture medium and cell lysates were loaded in each lane and electrophoresed on polyacrylamide gel. Immunoblotting was performed as previously described (Plouffe et al. 2012) . For quantification of the immunoreactive bands, western blot image acquisition was performed using a ChemiDoc MP system (Bio-Rad Laboratories, Hercules, CA, USA) and densitometry analysis was done with Image Lab software (version 5.1, Bio-Rad Laboratories, Hercules, CA, USA).
Immunoprecipitation of tau from neuronal culture medium and lysate After any treatment, the culture medium was collected from control and treated neurons and centrifuged at 1000 g for 10 min at 23°C to remove cell debris. tau was immunoprecipitated from the culture medium as previously described (Mohamed et al. 2014) .
Mesoscale immunoassay to measure tau in the neuronal culture medium The culture medium of control and treated cells was collected and centrifuged at 1000 g for 10 min at 23°C to remove cell debris. The amount of tau in the medium was determined by MSD MULTI-SPOT mouse total tau assay. This sensitive assay was used according to the manufacturer's instructions. All the experiments of tau secretion were analyzed in one 96-well 4-spot mouse total tau plate at the same time. The plate was read with Sector Imager 6000, a Meso Scale Discovery instrument.
Calculation of normalized tau secretion
In all the graphs presenting the quantification of tau secretion by western blotting, normalized tau secretion was calculated. To calculate normalized tau secretion, the signal of total tau in the medium (extau) was divided by the signal of total tau in the cell lysate (intau). The signal of intau was normalized to that of actin in the cell lysate.
LDH assay
Lactase dehydrogenase activity (LDH) in neuronal media was determined using a LDH Activity Assay Kit (Cayman Chemical Company, Ann Arbor, MI, USA) according to manufacturer instructions. The mean of final measurements (Abs 490 nm) of the enzyme activity was used for comparison between control and treated cells.
Immunofluorescence
HeLa cells and neurons grown on coverslips were fixed in 4% formaldehyde-phosphate-buffered saline for 10 min at 37°C. Immunofluorescence was performed as previously described (Mohamed et al. 2014) . HeLa cells were stained either with the anti-tau antibody, tau-1 (1 : 200) or A0024 (1 : 1000). Neurons were stained with the tau-1 antibody. Images were acquired on an axioplan Zeiss (Oberkochen, Germany) fluorescence microscope using a 639, 1.4 NA objective.
Electron microscopy HeLa cells were fixed in 0.1 M cacodylate buffer (pH 7.4) containing 1.0% glutaraldehyde (MECALAB, Montr eal, QC, Canada) and 1.5% tannic acid (Fisher Scientific, Pittsburgh, PA, USA). Cells were postfixed with 1% osmium tetroxide (EMS, Hatfield, PA, USA) in cacodylate buffer at 4°C. After several washes in buffer, cells were dehydrated in graded ethanol, infiltrated and embedded in Epon 812 (MECALAB), according to standard technique. Ultrathin sections were obtained using a Reichert Ultracut S ultramicrotome, and mounted on formvar-carbon coated nickel grids (MECALAB). Sections were stained with uranyl acetate and lead citrate and examination was performed with a Philips CM 100 electron microscope (Hillsboro, OR, USA).
Statistical analysis
All statistical analysis was run on data obtained from at least three independent experiments. Statistical significance was evaluated with a two-tailed paired Student's t-test or a one-way ANOVA followed by a post hoc Tukey test using GraphPad Prism 5.0; GraphPad Software Inc., San Diego, CA, USA. Findings were considered significant as follows: *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001.
Results

Suppression of Rab7A in primary cortical neurons and HeLa cells decreases tau secretion
In this study, we examined whether Rab7A is involved in tau release by neurons. To do this, at day 4 in vitro, primary rat cortical neurons were treated with Rab7A siRNA for 96 h to block its expression. As noted in Fig. 1 (a), Rab7A protein levels were decreased by~80% at 8 days in vitro. To evaluate tau secretion upon Rab7A depletion, the medium was collected and tau was immunoprecipitated using the antitau antibody, tau-5, allowing us to examine its profile in the medium by western blotting (Fig. 1a) (Mohamed et al. 2014) . For detection of tau in the immunoprecipitate, the A0024 antibody recognizing total tau was employed. Normalized tau secretion, which corresponded to the amount of total tau in the medium (extau) divided by that of total tau in the cell lysate (intau) was evaluated. The amount of intau was normalized to that of actin (Fig. 1b) . Depletion of Rab7A resulted in a significant decrease (~20%) of tau secretion (Fig. 1c) . To quantify the amount of tau in the medium, the MSD MULTI-SPOT mouse total tau assay was used (Fig. 1d ). As noted when tau was immunoprecipitated from the medium, this quantitative assay led us to conclude that the secretion of tau was significantly decreased upon Rab7A suppression ( Fig. 1c and d ). The amount of LDH, a biomarker of cellular cytotoxicity and cytolysis, was measured in the medium to make sure that the siRNA treatment did not compromise neuronal membrane integrity and survival (Fig. 1e) .
To further characterize the effects of Rab7A on tau secretion, we employed HeLa cells, a cellular system easier to manipulate than primary neuronal cultures. We previously reported that human TAU was secreted by HeLa cells (Plouffe et al. 2012) . Most importantly, TAU secretion by these cells shares several similarities with that of neurons. Firstly, tau secreted by both neurons and HeLa cells is hypophosphorylated, meaning less phosphorylated than intracellular tau, as revealed by its immunoreactivity to the tau-1 antibody recognizing dephosphorylated tau (Plouffe et al. 2012; Pooler et al. 2013; Mohamed et al. 2014) . Secondly, in both neurons and HeLa cells, tau secretion seems to occur through unconventional secretory pathways (Plouffe et al. 2012; Pooler et al. 2013; Mohamed et al. 2014) . Thirdly, in both neurons and HeLa cells, secreted tau is mainly free, meaning not found in vesicles (Plouffe et al. 2012; Pooler et al. 2013; Mohamed et al. 2014) . To verify whether RAB7A also influenced TAU secretion by HeLa cells, its endogenous expression was suppressed using siRNA. Serial transfections of RAB7A siRNA and the 0N4R isoform of human TAU (4R-TAU) were performed because we wished to suppress RAB7A expression before that of TAU began. Twenty-four hours after transfection of RAB7A siRNA, RAB7A expression was completely suppressed as endogenous RAB7A was not detectable by immunoblotting (Fig. 2a) . This time point was selected to transfect human TAU, which was over-expressed for 48 h. To analyze the amount of secreted TAU by HeLa cells, the medium was directly mixed with Laemmli buffer and processed for immunoblotting as previously described (Plouffe et al. 2012) . TAU in the cell lysate and medium was revealed using the A0024 antibody (Fig. 2b) . Normalized TAU secretion (exTAU/inTAU) was calculated as described for neurons ( Fig. 2c and d) . Interestingly, TAU secretion was significantly reduced by~50% in cells treated with RAB7A siRNA compared to cells treated with control siRNA (Fig. 2d) . We also analyzed the effects of RAB7A-dominant negative (T22N) and constitutively active (Q86L) The amount of secreted tau by neurons treated either with control or Rab7A siRNAs was measured using the MSD MULTI-SPOT mouse total tau assay. (e) Quantification of the levels of lactate dehydrogenase (LDH) in the medium of control or Rab7A siRNA-treated neurons. Data are shown as means AE SE for seven separate experiments (n = 7) *p < 0.05, **p < 0.01, t-test. mutants on TAU secretion. Both mutants were transfected 24 h before TAU transfection ( Figure S1 and Fig. 3a and d) . Forty-eight hours after TAU transfection, the medium was collected to examine its secretion. Accordingly, expression of RAB7A-T22N and RAB7A-Q86L decreased and increased TAU secretion, respectively ( Fig. 3c and f) .
Direct and indirect contribution of Rab7A to tau secretion To elucidate how RAB7A suppression could affect TAU secretion, we examined the protein levels of TAU in the cell lysate in HeLa cells and neurons. Interestingly, in HeLa cells, the decrease in TAU secretion upon depletion of RAB7A was correlated with a significant reduction in total TAU protein levels (~40%) in the cell lysate (Fig. 2c) . Four TAUpositive bands representing different phosphorylated species were found in the cell lysate of HeLa cells over-expressing 4R-TAU as reported in our previous study (Plouffe et al. 2012) . The four bands were included in the quantification of TAU protein levels, which were normalized to those of actin. Upon RAB7A depletion, the lowest band was always the most importantly decreased (Fig. 2b) . The lowest band corresponds to the TAU species secreted by HeLa cells (Plouffe et al. 2012) . Interestingly, the decrease in TAU secretion induced by RAB7A dominant negative mutant was also correlated with reduced protein levels of TAU in the cell lysate ( Fig. 3a and b) . To make sure that the decrease in TAU protein levels was not caused by a reduction in TAU synthesis in cells depleted of RAB7A, qPCR was used to measure the TAU mRNA levels ( Figure S2a) . No significant decrease but instead a small increase in TAU mRNA was noted upon RAB7A suppression and TAU over-expression. Therefore, the decrease in TAU protein levels observed by western blotting indicated that the suppression of Rab7A increased TAU protein degradation. We then verified whether the protein levels of other proteins were also decreased upon RAB7A suppression. GFP, a cytosolic protein, and BIP, a protein located at the endoplasmic reticulum were over-expressed. Interestingly, only the protein levels of GFP were decreased ( Figure S2b and c) indicating that cytosolic proteins like tau were more degraded upon RAB7A suppression.
From the above observations, one could speculate that the decrease in TAU secretion could result from a decrease in TAU protein levels in the cell lysate. We examined whether TAU secretion was linked to its intracellular protein levels. Two approaches were used to examine this possibility in HeLa cells. Firstly, increasing concentrations of TAU cDNA were used to induce a low to high TAU protein expression in HeLa cells ( Figure S3 ). In all cases, TAU secretion was increased when TAU protein levels in the cell lysate was increased in the presence or absence of RAB7A. This indicated that the decrease in TAU in the cell lysate upon RAB7A suppression contributed to the reduced TAU secretion. Secondly, tau is known to be degraded by the proteasome. HeLa cells were treated with the proteasome inhibitor MG-132. Since MG-132 was toxic to HeLa cells when it was applied for an extended period of time (24 h), cells were only treated for 6 h. As shown in Figure S4 (a) and (b), treatment of RAB7A-depleted cells with MG-132 mainly decreased the degradation of the lowest TAU-positive band as shown by its accumulation. This lowest band corresponded to a C-terminal truncated form of TAU (cleaved inTAU) as it was not detected by the anti-tau antibody tau46 recognizing an epitope located between the amino acids 428 and 441 ( Figure S4a) . Furthermore, this band was detected by the tau-1 antibody directed against dephosphorylated tau. These observations indicated that Cterminal truncated and dephosphorylated TAU was more All graphs show quantified densitometry of protein levels expressed as % relative to either control siRNA or empty vector. In all graphs, data are shown as means AE SE for three separate experiments performed in duplicate, n = 6. *p < 0.05, ***p < 0.001, t-test; all other comparisons are not significant (n.s.).
readily degraded by the proteasome upon the suppression of RAB7A. As expected, the increase of the lowest TAU band in the cell lysate when the proteasome was blocked was correlated with an increase in tau secretion confirming that the intracellular TAU protein levels influenced TAU secretion ( Figure S4c) .
We then verified whether in neurons, the decrease in tau secretion upon Rab7A deletion was also correlated with a decrease in tau protein levels in the cell lysate. No significant change in tau protein levels was noted in the lysate of neurons depleted of Rab7A (Fig. 1b) . All together, the above observations indicated that Rab7A indirectly and directly regulated tau secretion. The indirect effects were only observed in HeLa cells where upon Rab7A suppression, a reduction in TAU in the cell lysate was correlated with a decrease in tau secretion. However, in both neurons and HeLa cells, direct effects were observed. In neurons, a reduction in tau secretion but not of its protein levels was noted. In HeLa cells, the reduction of TAU secretion was always higher (~50%) than its decrease in the cell lysate (~40%) indicating that RAB7A could directly act on TAU secretion. Lastly, also consistent with a direct role of Rab7A in tau secretion in HeLa cells, RAB7A-CA mutant enhanced TAU secretion without increasing its protein levels in the cell lysate ( Fig. 3d-f ).
tau is found in Rab7A-positive structures in both neurons and in HeLa cells To further investigate the direct role of Rab7A in tau secretion, their co-localization was examined in both neurons and HeLa cells. Primary cortical neurons were transfected with a RAB7A constitutively active (Q86L) form fused to GFP (GFP-RAB7A-CA) and HeLa cells were co-transfected GFP-RAB7A-CA and human TAU. The constitutively active (Q86L) form of RAB7A instead of wild-type RAB7A was used to make sure that RAB7A was activated when over-expressed in neurons and HeLa cells. After 48 h of transfection, neurons and HeLa cells were fixed and stained either with the A0024 antibody detecting total tau or with the tau-1 antibody that recognizes dephosphorylated tau shown in our previous study to be secreted by both neurons and HeLa cells (Plouffe et al. 2012; Mohamed et al. 2014) . In neurons, a partial co-localization was noted between tau and RAB7A-positive structures located in the axon (Fig. 4a) . In HeLa cells presenting low TAU protein levels, TAU was found associated with microtubules ( Figure S5a ). In cells presenting moderate TAU protein levels, the staining of TAU appeared cytoplasmic and diffuse ( Figure S5b ). This latter distribution was reminiscent to that noted in AD when upon its detachment of the axonal microtubules, TAU accumulates in the soma of neurons (Iqbal et al. 2016) . The colocalization between RAB7A and TAU was observed in the cytoplasm as well as in short processes emerging from the cell surface of HeLa cells (Fig. 4b and c) . The colocalization was observed with the A0024 and tau-1 antibodies. The presence of tau in Rab7A-positive structures supported a role of this Rab in tau secretion in both neurons and HeLa cells.
We and others reported that tau secretion occurs through unconventional pathways (Plouffe et al. 2012 ; Pooler et al. 2013; Mohamed et al. 2014) . Knowing that Rab7A contributes to the trafficking and biogenesis of late endosomes, autophagasomes, autolysosomes, and lysosomes involved in unconventional secretion, we examined the impact of Rab7A suppression on these structures by electron microscopy. Rab7A is implicated in the maturation of autophagic vacuoles (Bucci et al. 2000; Jager et al. 2004) . Autophagosomes can directly fuse with lysosomes or fuse with multivesicular bodies (MVBs) to form amphisomes before fusing with lysosomes (Roizin et al. 1967; Gordon and Seglen 1988; Berg et al. 1998) . The formation of amphisomes represents the major autophagic pathway in HeLa cells (Filimonenko et al. 2007) . Amphisomes are characterized by the presence of electron dense material and intraluminal vesicles. By transmission electron microscopy, we noted a significant increase in the number of MVBs upon suppression of RAB7A that was accompanied by a modest increase in amphisomes (Fig. 5a-e) . This corroborates previous studies demonstrating that Rab7A suppression induced an accumulation of MVBs and that Rab7A is involved in the fusion of autophagosomes/amphisomes with lysosomes (Vanlandingham and Ceresa 2009; Ao et al. 2014) . Furthermore, MVBs appeared larger in RAB7A-depleted cells than in control cells as previously reported (Fig. 5a and b) . The number of amphisomes became significantly higher in cells depleted of RAB7A than control cells when TAU was over-expressed (Fig. 5e) . This was consistent with previous studies reporting an accumulation of autophagic vacuoles in tau transgenic mice (Lin et al. 2003; Ozcelik et al. 2013) . Some double membrane macroautophagic vacuoles were also observed (Fig. 5c) . The accumulation of MVBs and amphisomes indicated that upon suppression of RAB7A in HeLa cells, the autophagic flux was impaired. To further confirm this, we investigated the levels of LC3I and LC3II by immunoblotting (Fig. 5f ). The accumulation of the membrane-bound LC3II, a commonly used marker for defects in the autophagic flux, correlates with an accumulation of autophagic vacuoles (Klionsky et al. 2012) . The amount of LC3II was approximately 2.5 times higher in the RAB7A-depleted cells when compared with cells transfected with control siRNA (Fig. 5g) . Furthermore, the protein levels of p62, a multifunctional protein that binds directly to LC3 and can be degraded within autolysosomes, were significantly increased in cells depleted of RAB7A compared to control cells (Fig. 5h) (Ichimura et al. 2008) . Both morphological and biochemical analysis of autophagic markers indicated that autophagy could be compromised in HeLa cells depleted of RAB7A. It was previously demonstrated that the impairment of autophagosome-lysosome fusion as noted when Rab7A was suppressed could lead to an increase in unconventional secretion (Ejlerskov et al. 2013) . In contrast to this study, we observed a reduction in tau secretion upon an impaired autophagosome-lysosome fusion by Rab7A suppression. This discrepancy could be explained by the fact that Rab7A itself and not its effects on autophagosome-lysosome fusion plays a role in tau secretion. This would be consistent with a direct role of Rab7A in tau secretion.
Finally, we next examined the phosphorylation state of TAU upon deletion of RAB7A. In HeLa cells treated with control siRNA, over-expressed human TAU was detected with the antibodies directed against TAU phosphorylated either at threonine 181 (T181), serine 202 (S202), serine 404 (S404) or serine 422 (S422) as noted previously (Fig. 6a ) (Plouffe et al. 2012) . Deletion of RAB7A significantly decreased TAU phosphorylation (Fig. 6a and b) . Remarkably, the phosphorylation at T181 and S422 was completely abolished (Fig. 6a) . The phosphorylation at S202 and S404 was also significantly reduced (Fig. 6b) . Consistent with a reduction in tau phosphorylation, non-phosphorylated tau at S199/202/T205 recognized by the tau-1 antibody was increased in HeLa cells depleted of RAB7A (Fig. 6a and  b) . In neurons, the suppression of Rab7A also resulted in a decrease in tau phosphorylation at S202 and S422 ( Fig. 6c  and d) . Based on our previous study where we reported that hyperphosphorylation resulted in an increase in TAU secretion in HeLa cells, the decrease in tau phosphorylation upon Rab7A suppression could contribute to its reduced secretion.
Discussion
In recent studies, RAB7 expression and protein levels were shown to be increased at early stages of AD (Ginsberg et al. 2010a (Ginsberg et al. ,b, 2011 Tiernan et al. 2016 ). However, the functional impact of these changes remains elusive. In this study, we demonstrated that Rab7A regulates tau secretion. Furthermore, a partial co-localization of tau and Rab7-positive structures in both neurons and HeLa cells indicates that a late endosomal compartment could be involved in tau secretion. Collectively, the present data demonstrate that Rab7A is involved in tau secretion and therefore its up-regulation, reported in AD, could contribute to the extracellular accumulation of aggregated TAU species that could be responsible for the propagation of TAU pathology in the brain (Lewis and Dickson 2016) .
Contribution of Rab7A to tau secretion
In both neurons and HeLa cells, Rab7A suppression resulted in a decrease in tau secretion. tau was found in Rab7A-positive structures in both neurons and HeLa cells. Since Rab7A is associated with late endosomal compartments, the present data indicate that such a compartment could be involved in tau secretion. This is consistent with the fact that late endosomal compartments were shown to be able to fuse with the plasma membrane to release their content in the extracellular space (Fevrier and Raposo 2004; Lei et al. 2012) . In RAB7A deleted HeLa cells, we noted an impairment of the autophagic flux. In a previous study, impaired autophagosome-lysosome fusion was linked to an increased unconventional secretion of alpha-synuclein, a protein involved in Parkinson's disease (Ejlerskov et al. 2013 ). This was explained by the fact when alpha-synuclein could not reach the lysosomes to be degraded, it remained in autophagosomes/late endosomes that could fuse with the Data are shown as means AE SE for three independent experiments, n = 3. *p < 0.05, **p < 0.01, or ****p < 0.0001, t-test; all other comparisons are not significant (n.s.). AU = arbitrary units.
plasma membrane to release it in the extracellular space. In this study, the impairment of autophagosome-lysosome fusion induced by RAB7A suppression was not correlated with an increase but rather to a decrease in TAU secretion.
This could indicate that tau and alpha-synuclein are secreted by different pathways. Another explanation could be that the involvement of Rab7A in tau secretion is not dependent on its effects on the autophagosome-lysosome fusion. For (pS202), S404 (pS404), and S422 (pS422) from rat cortical neurons treated either with control or RAB7A siRNA. Other experimental details in Materials and Methods. (d) Quantified densitometry of tau phosphorylated at T181, S202, S404, and S422 from rat cortical neurons treated either with control or RAB7A siRNA. The signal of phosphorylated tau was normalized to that of actin. For (b) data are shown as means AE SD for three separate experiments performed in duplicate n = 6. For (d) data are shown as means AE SD for three separate experiments n = 3. All graphs show quantified densitometry of protein levels expressed as % relative to control siRNA, *p < 0.05 or **p < 0.01, t-test.
example, Rab7A could be involved in the targeting and/or the increase the access of tau its secretory pathways. It is still unclear how tau would reach a late endosomal compartment. The pool of secreted tau presents low levels of phosphorylation. In previous studies, it was demonstrated that tau located at the plasma membrane was weakly phosphorylated (Maas et al. 2000; Pooler et al. 2012) . This pool of tau associated with the plasma membrane could be internalized and then could be transported through the endosomal system in Rab7A-positive structures. tau-containing endosomal structures could be recycled back to the plasma membrane resulting in the release of tau in the extracellular space. This mechanism was reported for the secretion of alpha-synuclein (Liu et al. 2009 ). Collectively, the above observations support a role of Rab7A in tau secretion. However, a Rab7A-dependent pathway is not the sole pathway used by tau since its secretion was only partially blocked by Rab7A suppression. In RAB7A-depleted HeLa cells, a pool of TAU was degraded by the proteasome. It was recently reported that the suppression of Rab7A could enhance the proteasomal degradation of two members of epidermal growth factor receptors, EGFR and Her2 (Wang et al. 2012) . The mechanisms involved in Rab7A-dependent degradation by the proteasome remain to be elucidated. In this study, the effects of RAB7A suppression on degradation was only noted on over-expressed proteins in HeLa cells. This was the case of TAU and GFP but not BIP. Interestingly, all the above proteins except BIP are found in late endosomes/ MVBs. In this study, tau was shown to be localized to Rab7A-positive structures. In the case of GFP, a recent study reported that it was found in late endosomal structures, which were involved in its unconventional secretion (Lee et al. 2016) . Most interestingly, in this recent study, it was reported that late endosomes were involved in the unconventional secretion of proteins accumulating in the cytoplasm when the proteasome activity was deficient (Lee et al. 2016) . Based on this recent study, one can speculate that the over-expression of TAU in HeLa cells leading to its accumulation in the cytoplasm would result in its unconventional secretion through a late endosomal structure. In this recent study, they could not confirm that late endosomes were involved in tau secretion since they could not detect tau in the culture medium in any of their experimental conditions. The above observations indicate that any condition leading to the accumulation of cytosolic proteins such as the impairment of the degradative pathways observed in AD might drive neurons to use alternative clearance mechanisms such as secretion. In a recent study, phosphorylated and aggregated tau was shown to interact with the proteasome and to impair its function (Myeku et al. 2016) . This indicates that tau could contribute to its accumulation and thereby to the increase in its secretion in AD. This deserves to be further investigated.
Discrepancy between HeLa cells and primary cortical neurons
In both HeLa cells and neurons, the suppression of Rab7A decreased tau secretion. In HeLa cells, this decrease in secretion was correlated with a decrease in TAU protein levels in the cell lysate. However, we failed to detect a decrease in intracellular tau in rat primary cortical neurons when Rab7A was suppressed indicating that in neurons, Rab7A might not be involved in tau degradation as noted in HeLa cells. This apparent discrepancy between HeLa cells and neurons could be imputable to the fact that HeLa cells over-expressing human TAU are more representative of neurons in AD that present an aberrant accumulation of TAU in their cytoplasm upon its detachment from axonal microtubules than control neurons (Iqbal et al. 2016) . These results indicate that a protein aberrantly accumulating in the cytoplasm would be targeted to the proteasome when Rab7A is depleted. In control neurons where tau protein levels are normal, this mechanism would not take place. In such a situation, Rab7A depletion would only affect tau secretion. Lastly, it is important to mention that the suppression of RAB7A was complete in HeLa cells, whereas a low amount of Rab7A remained detectable in neurons. A complete deletion of Rab7A could be necessary for altering tau protein levels and allowing its detection by western blotting.
Our results clearly demonstrated that Rab7A could alter the protein levels of intracellular TAU in HeLa cells. However, such an alteration was not observed in our neuronal cultures as recently reported in another study. In that recent study where the relationship between Rab7A and tau was examined in Creutzfeldt-Jakob disease, it was reported that the suppression of Rab7A resulted in a decrease in endogenous tau protein levels in mouse primary cortical neurons (Zafar et al. 2016) . This discrepancy with our results could be explained by different levels of Rab7A depletion and/or by differences in the neuronal cultures. Our experiments were performed in wild-type rat neurons, whereas murine neurons carrying the cellular prion protein were used in the other recent study. Furthermore, the composition of their culture media was different from ours, which could influence the distribution and expression levels of tau in neurons. The role of Rab7A in tau degradation remains to be fully elucidated. Lastly, the degradative pathways of tau in neurons are still a matter of debate. It is necessary to better understand these pathways before one can elucidate the role of Rab7A in tau degradation.
Our data revealed that upon Rab7A deletion, tau phosphorylation at S202 and S422 was significantly reduced in both neurons and HeLa cells. However, the phosphorylation at T181 and S404 was only affected in HeLa cells. This discrepancy could be caused by the presence of a different set of kinases and phosphatases in HeLa cells and neurons. We recently obtained data indicating that GSK3b would contribute to the reduction in T181 and S404 in HeLa cells (unpublished data). We observed an increase in MVBs upon Rab7A suppression in HeLa cells. Such structures were shown to be able to sequester GSK3b. Most interestingly, this sequestration was previously reported to prevent the phosphorylation of GSK3b substrates such as b-catenin involved in the Wnt signaling pathway (Taelman et al. 2010) . In HeLa cells, over-expression of GSK3b could reestablish phosphorylation of TAU at T181 and S404 but not at S202 and S422 sites indicating that other kinases are affected by RAB7A deletion (unpublished data).
Impact of the modulation of tau phosphorylation by Rab7A on tau secretion In a previous study, we showed that hyperphosphorylation increased tau secretion by HeLa cells (Plouffe et al. 2012) . Therefore, Rab7A could also exert negative effects on tau secretion by decreasing its phosphorylation in both HeLa cells and neurons. However, in a previous study, we reported that tau secretion was significantly increased by starved neurons presenting a decrease in tau phosphorylation (Mohamed et al. 2014) . Furthermore, we also reported that inhibition of the lysosomal function by leupeptin increased tau secretion. This increase was not correlated with any change in tau phosphorylation (Mohamed et al. 2014) . Lastly, it is important to mention that we reported that in HeLa cells, mimicking of TAU cleavage by caspase 3 increased TAU secretion (Plouffe et al. 2012) . It was previously reported that phosphorylation could affect the cleavage of tau by caspase 3 (Guillozet- Bongaarts et al. 2006) . Therefore, tau phosphorylation could indirectly modulate tau secretion by influencing its cleavage. All together, the above observations indicate that phosphorylation in not the sole factor regulating tau secretion and its contribution to tau secretion could vary depending on the insult inducing tau secretion.
Conclusion
Our data revealed that Rab7A is involved in tau secretion indicating that the increased expression of RAB7A noted in AD could enhance TAU secretion linked to the propagation of TAU pathology. It would be important to further define the pathways involving RAB7 in TAU secretion to elaborate a therapeutic strategy that would abrogate it and thereby the propagation of tau pathology in AD brain (Lewis and Dickson 2016) .
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